Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.

Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.

Inclusion Criteria:

• men and women aged 18 to 65 years with schizophrenia;
• PANSS total score of at least 70 at screening and baseline;
• at least 2 more than 4 points in 7 of PANSS-P;
• informed consent.

Exclusion Criteria:

• allergy with iloperidone or risperidone;
• psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment;
• any other primary Axis 1 psychiatric diagnosis;
• a history of alcohol or drug dependence in recent 1 year;
• at imminent risk of harm to self or others;
• systolic blood pressure≤90mmHg。